期刊文献+

浅析循证医学指导下的乳腺癌辅助内分泌治疗

Adjuvant endocrine therapy of breast cancer under the guidance of evidence-based medicine
原文传递
导出
摘要 辅助内分泌治疗是乳腺癌内分泌治疗中的重要组成部分,本文通过解读相关临床试验、Meta分析、国内外治疗指南及国际著名会议中所涉及的循证医学数据,浅析绝经前辅助内分泌治疗的选择、他莫昔芬辅助内分泌治疗的时限、他莫昔芬序贯芳香化酶抑制剂辅助内分泌治疗的时间截点等几个较有争议的问题。 Adjuvant endocrine therapy is an important part of endocrine therapy of breast cancer. Some problems are controversial such as the choice of premenopausal adjuvant endocrine therapy, how long tamoxifen should be taken in adjuvant endocrine therapy, time limit of tamoxifen should be taken before followed by aro- matase inhibitors. The article analyzed data from evidence-based medicine of clinical trials, Meta-analysis, treat- ment guidelines both at home and abroad, international famous conventions to interpret the above problems.
作者 章国晶 谢晓冬 Zhang Guo-ring Xie Xiaodong(Oncology Diagnosis and Treatment Center, the General Hospital of Shenyang Military Region, Shenyang 110840, China)
出处 《中华内分泌外科杂志》 CAS 2016年第5期353-355,共3页 Chinese Journal of Endocrine Surgery
基金 国家十二五重大新药创制平台子课题(2012ZX09303016-002) 辽宁省科技攻关计划课题(2012225019)
关键词 乳腺肿瘤 内分泌治疗 辅助治疗 Breast carcinoma Endocrine therapy Adjuvant therapy
  • 相关文献

参考文献15

  • 1Williams N, Harris LN. The renaissance of endocrine therapy in breast cancer[J]. Curr Opin Obstet Gynecol,20 14,26 (1 ) :41-47. DOl: 1 0.1097/GCO.OOOOOOOOOOOOOO39.
  • 2Sestak I, Cuzick J. Markers for the identification of late breast cancer recurrence[J]. Breast Cancer Res,2015,17:10. DOI:1O.11861 s13058-015-0516-0.
  • 3Dalmau E, Armengol-Alonso A, Mul'loz M. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer[J]. Breast,2014,23 (6):710-720. DOI:1O.10161j.breast. 2014.09.006.
  • 4Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials[J]. Lancet,1998,351 (9114 ):1451-1467. DOl: http://dx.doi.orgl10.10161 S0140-6736(97)11423-4.
  • 5Francis PA, Regan MM, Fleming GF, et aI. Adjuvant ovarian suppression in premenopausal breast canceIfJ]. N Engl J Med,2015,372 (5):436-446. DOI:1O.10561NEJMoa1412379.
  • 6Tevaarwerk AJ, Wang M, Zhao F, et aI. Phase m comparison of Tamoxifen versus Tamoxifen plus ovarian function suppression in premenopausal women with node-negative,hormone receptor-positive breast cancer(E-3193,1NT-0142): a trial of the Eastern Cooperative Oncology Group[J]. J Clin Onco1,2014,32 (35):3948-3958. DOI:10.1200/JCO.2014.55.6993.
  • 7Jain S, Santa-Maria CA, Gradishar WJ. The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer[J]. Oncology(Williston Park),2015,29(7): 473-478,481. PMID:26178334.
  • 8Francis P A, Regan MM, Fleming GF, et aI. Adjuvant ovarian suppression in premenopausal breast cancer[J]. N Engl J Med,2015, 372(5):436-446. DOI:10.1056INEJMoa1412379.
  • 9Pagani 0, Regan MM, Francis P A Exemestane with ovarian suppression in premenopausal breast cancer[J]. N Engl J Med,2014,371 (14 ):1358-1359. DOI:10.1056INEJMc1409366.
  • 10Dunn BK, Ford LG. Breast cancer prevention:results of the National Surgical Adjuvant Breast and Bowel Project(NSABP)breast cancer prevention trial (NSABP P-1:BCPT)[J]. Eur J Cancer,2000, 36 (4) :549-S50.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部